CYP19A1 and breast carcinoma: This estrogen dependence has led to diverse therapeutic approaches to treat breast cancer that include inhibiting the production of estrogen via the enzyme aromatase and targeting one of its receptors (ERα) through either inhibition or degradation (4, 5).